Skip to main content
. Author manuscript; available in PMC: 2018 Jun 20.
Published in final edited form as: Stroke. 2008 Oct 9;39(12):3389–3396. doi: 10.1161/STROKEAHA.108.523480

Figure 1.

Figure 1

Effect of EGb761 pre- and posttreatment on stroke outcomes. For the pretreatment study, wild-type (WT) and HO-1 knockout (HO-1−/−) mice were pretreated for 7 days with EGb761 and subjected to transient middle cerebral artery occlusion (MCAO) and 24 hours of reperfusion before being assessed for neurological deficit (A) and infarct volume (B). For the posttreatment study, WT mice were subjected to transient MCAO and given 100 mg/kg EGb761 either 5 minutes or 4.5 hours into the reperfusion. Neurological deficit scores (C), and corrected infarct volumes (D) were assessed after 24 or 72 hours of reperfusion. Data are expressed as mean±SEM; n=8 to 12 per group. *P<0.05, **P<0.01 vs vehicle-treated control, #P<0.05 vs the 5-minute exposure.